EcoDrugPlus

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSCHAG00000001587
Gene Symbol: FGFR2
1 Cross references
221 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSCHAG00000018255
Gene Symbol: FGFR3
1 Cross references
149 Possible Orthologues:

Fibroblast Growth Factor Receptor Like 1

Ensembl ID : ENSCHAG00000011694
Gene Symbol: FGFRL1
2 Cross references
176 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSCHAG00000016175
Gene Symbol: FLT1
1 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSCHAG00000001387
Gene Symbol: FLT4
1 Cross references
197 Possible Orthologues:

Folate Receptor Beta

Ensembl ID : ENSCHAG00000010214
Gene Symbol: FOLR2
1 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSCHAG00000001082
Gene Symbol: LOC105901971
3 Cross references
319 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSCHAG00000007601
Gene Symbol: LOC105901628
2 Cross references
340 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSCHAG00000007609
Gene Symbol: LOC105901627
2 Cross references
306 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSCHAG00000020829
Gene Symbol: FRK
3 Cross references
217 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSCHAG00000019452
Gene Symbol: GLA
1 Cross references
197 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSCHAG00000007313
Gene Symbol: LOC105891002
3 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).